LFA102 treatment (300 mg/kg) significantly reduced PRLR signaling and tumor growth in this rat mammary cancer model as a monotherapy and combination with letrozole (aromatase inhibitor, 10 μg/kg). Here, PRLR is linked to breast cancer.